109 results about "Metformin" patented technology

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The utility model discloses a metformin hydrochloride electrochemical analysis device which comprises a shell, and one side of the shell is provided with an electric sensor interface; the power supply unit is arranged in the shell and is used for generating polarization voltage; the silk-screen printing electrode electric sensor is electrically connected with the power supply unit and comprises a flexible electrode base body, a working electrode, a counter electrode, a reference electrode, an insulating layer, a wiring terminal and an electrode connecting wire, and the working electrode, the counter electrode, the reference electrode, the insulating layer, the wiring terminal and the electrode connecting wire are arranged on the flexible electrode base body; the surface of the working electrode is modified with an imprinted polymer with selective recognition on metformin hydrochloride; the signal processing unit is arranged in the shell and comprises a shunt resistor, an operational amplifier, a signal converter, a data storage chip and a microprocessor which are electrically connected in sequence; the display screen is electrically connected with the microprocessor and is used for displaying the converted concentration value; the method has the advantages that the metformin hydrochloride can be rapidly and accurately detected, and the use is relatively convenient.

The application belongs to the technical field of bioactive nanomaterials, and particularly relates to a metformin nanomaterial, a preparation method and application thereof. The average hydrodynamic diameter of the nanomaterial is less than 500 nm, and the nanomaterial is prepared by a preparation method comprising the following steps: self-assembly of metformin and polyphenols to obtain metformin-polyphenol nanoparticles; reaction of bisphosphonate and polyethylene glycol to obtain bisphosphonate-polyethylene glycol organic segments; and reaction of the metformin-polyphenol nanoparticles and the bisphosphonate-polyethylene glycol organic segments to obtain the nanomaterial. The metformin, polyphenol, polyethylene glycol and bisphosphonate are prepared into the metformin-loaded nanomaterial through specific reactions, the systemic delivery of metformin is realized, the efficacy and bioavailability of metformin on osteoporosis are improved, and the bone targeting of metformin is also improved.

The application discloses a preparation method of CCR2+ gamma delta T cells with anti-tumor activity and migration ability, and belongs to the technical field of cells; the method comprises the following steps: step (1), PBMC of peripheral blood of a healthy person is extracted, inoculated into complete culture medium, and added with zoledronic acid, IL-15 and metformin, and then is cultured in a T25 culture bottle; step (2), complete culture medium is supplemented, the cell concentration is adjusted, and then the cells are transferred into a T75 culture bottle for culture; step (3), complete culture medium is supplemented, the cell concentration is adjusted, glucocorticoid and nicotinamide are added, and then the cells are transferred into a T150 culture bottle for culture; step (4), cells are collected at D6, rinsed with normal saline, resuspended with complete culture medium, the cell concentration is adjusted, and then the cells are inoculated into a T300 culture bottle for culture; and step (5), complete culture medium is supplemented every two days from D8 to D16, the cell concentration is maintained, and then the cells are harvested at D16 to obtain CCR2+ gamma delta T cells.

Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The invention relates to the technical field of analytical chemistry, in particular to a method for detecting metformin based on gold nano-cluster fluorescent test paper. In order to solve the problem of inconvenience in metformin detection, the invention provides the following technical scheme: the method comprises the following steps: S1, preparing an ATT-AuNCs solution; s2, preparing gold nano-cluster fluorescent test paper; s3, constructing a metformin detection standard curve; S31, preparing a metformin concentration gradient solution; s33, performing signal processing and curve fitting; s4, detecting metformin in a to-be-detected sample; S41, pretreating the sample; s42, test paper detection and signal acquisition; and S43, calculating the concentration. The ATT-AuNCs gold nano-cluster adopted by the invention has the remarkable advantages of strong photoluminescence performance, large Stokes shift, good biocompatibility, easiness in synthesis and surface modification and the like, the fluorescent test paper constructed based on the gold nano-cluster is convenient to carry, the detection of metformin can be realized only by virtue of an ultraviolet lamp, large-scale instruments and equipment are not needed, and the cost is low. The method is simple and rapid, has visual results, and can be used for determining metformin in drugs and health care products.

The invention discloses a synthesis method of a fullerene nano material with glycolipid metabolism regulation capability, and belongs to the technical field of material science and biomedical engineering. The fullerene and the metformin are combined through chemical bonds, the strong oxidation resistance of the fullerene and the hypoglycemic effect of the metformin are exerted at the same time, the synergistic treatment effect is formed, and the drug composition is superior to a single drug; active oxygen in cells can be efficiently removed, oxidative stress is effectively relieved, and the functions of pancreatic beta cells are protected; through structural modification, the problem of low bioavailability caused by hydrophobicity of fullerene and hydrophilicity of metformin is solved, and the solubility and absorption efficiency of the medicine are improved; in conclusion, through chemical combination of the fullerene and the metformin, a dual-mechanism synergistic effect of oxidation resistance and blood sugar reduction is achieved, the treatment effect is remarkably improved, meanwhile, good safety and biocompatibility are achieved, and important application value is achieved in the field of treatment of the type II diabetes mellitus.

The application discloses a metformin-induced stem cell-derived extracellular matrix material and a preparation method and application thereof, and relates to the technical field of biological materials. The preparation method comprises the following steps: inoculating mesenchymal stem cells on a pretreated culture carrier, and using a culture system containing metformin to induce and treat the mesenchymal stem cells; adding ascorbic acid to induce and culture extracellular matrix secretion; carrying out decellularization treatment and nuclease treatment on the metformin-induced extracellular matrix; collecting the metformin-induced stem cell-derived extracellular matrix, mixing the metformin-induced stem cell-derived extracellular matrix with an aqueous medium, and enriching and forming an extracellular matrix precipitate through centrifugal treatment; and sequentially carrying out freezing treatment and thawing treatment on the extracellular matrix precipitate to obtain the metformin-induced stem cell-derived extracellular matrix material. The metformin is used to induce the mesenchymal stem cells to secrete an engineered extracellular matrix, and the engineered extracellular matrix is used to promote the repair of bone defects, skeletal muscle injuries and musculoskeletal joint defects in a diabetic environment.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

The invention relates to a copper / temozolomide / metformin nano prodrug as well as a preparation method and application thereof. The nano prodrug is formed by coordination self-assembly of temozolomide, copper ions and metformin, the mass fraction of temozolomide is 20%-60%, the mass fraction of copper ions is 20%-40%, and the mass fraction of metformin is 1%-60%. The invention provides a preparation method of a nano prodrug, which comprises the following steps: on the basis of a copper / temozolomide prodrug, introducing a metformin aqueous solution, and stirring and reacting in a water phase at normal temperature to obtain a three-component nano prodrug with glutathione response release characteristic. The prodrug is clear in structure and stable in particle size, copper ions and temozolomide can be released in a tumor microenvironment to induce copper death, and efficient treatment of drug-resistant glioblastoma is achieved in cooperation with metabolic intervention of metformin. Compared with the prior art, the preparation method disclosed by the invention is simple and convenient, an additional carrier is not needed, and the prodrug has good targeting property, biodegradability and treatment effect and has a good application prospect.

The present disclosure relates to methods of treating diseases such as neurological, muscular and proliferative diseases using a combination of metformin and rapamycin.

The present application relates to the technical field of biological medicine, and in particular to a pharmaceutical composition for treating hepatocellular carcinoma and application thereof, wherein the pharmaceutical composition comprises metformin or a pharmaceutically acceptable salt thereof and obeticholic acid or a pharmaceutically acceptable salt thereof, and the weight ratio of the metformin to the obeticholic acid is 1:0.05-0.2. It is found for the first time that the combination of metformin and farnesol X receptor agonist can regulate the AMPK / mTOR pathway and the immune recruitment mediated by CXCL16 in a synergistic manner, inhibit the proliferation of tumor cells, repair the recruitment function of NKT cells in the microenvironment of hepatocellular carcinoma, and realize the dual anti-tumor effect of metabolic inhibition and immune enhancement. Animal experiments show that the tumor inhibition rate of the combination drug group is significantly better than that of the single drug group, and the safety is good.

The invention provides a preparation form and a preparation method of metformin. The preparation is composed of a tablet core and a controlled release film wrapping the tablet core, and the controlled release film is provided with at least one channel which allows the metformin or the pharmaceutically acceptable salt of the metformin to be released from the tablet core in a water phase environment. The design of the dosage form can control the release of the metformin or the pharmaceutically acceptable salt of the metformin to be less than 30% in 4 hours and less than 92% in 24 hours in a medium with the temperature of 37 DEG C and the pH value of 6.8. The design of the dosage form can control the plasma concentration of the metformin to reach the peak value at about 8-24 after the metformin or the pharmaceutically acceptable salt of the metformin is taken for a single time.

The invention discloses a trigonelline metformin salt and a preparation method thereof, and the preparation method comprises the following steps: providing a resin column filled with anion exchange resin, treating the resin column with a salt solution for ion replacement activation to obtain an activated resin column, anions of the salt are chloride ions, bromide ions, acetate ions, malate ions, lactate ions, tartrate ions or citrate ions; enabling the trigonelline metformin iodized salt solution to pass through an activated resin column, and selectively collecting the exchanged solution; and carrying out concentration treatment on the collected exchanged solution to obtain the trigonelline metformin salt. In combination with a specific embodiment, compared with a trigonelline metformin iodate, the solubility of the trigonelline metformin salt prepared by the preparation method of the trigonelline metformin salt provided by the invention in water is greatly improved, so that the application range of the trigonelline metformin salt is greatly expanded.

The invention relates to design and application of peptidyl hydrogel, in particular to an RXD or RXDX peptide motif, a design method of the RXD or RXDX peptide motif, application of the RXD or RXDX peptide motif in preparation of medicine for treating diseases by reducing 4-GBA and the peptidyl hydrogel. In order to overcome the defects that in the prior art, osteogenesis-related growth factors cannot completely recover the osteogenesis effect in a hyperglycemia environment, or compounds such as metformin and the like can only partially reverse MSCs dysfunction, the curative effect on hyperglycemia bone regeneration deficiency is limited, or MSCs transplantation and extracellular vesicle (EVs) treatment face curative effect limitation and safety risk, the invention provides a preparation method of the osteogenesis-related growth factors. The X in the RXD or RXDX peptide motif is determined through virtual screening and affinity scoring, and finally the peptide motif with the best electrostatic adsorption effect is obtained. Meanwhile, the invention further provides application of the RXD or RXDX peptide motif and peptidyl hydrogel based on the peptide motif.

The invention belongs to the technical field of bioactive nano materials, and particularly relates to a metformin nano material as well as a preparation method and application thereof. The average hydrodynamic diameter of the nano material is less than 500 nm, and the nano material is prepared by the preparation method comprising the following steps: self-assembling metformin and a polyphenol compound to obtain metformin-polyphenol nano particles; the preparation method comprises the following steps: reacting bisphosphonate with polyethylene glycol to obtain a bisphosphonate-polyethylene glycol organic chain segment; the metformin-polyphenol nano particles and the diphosphonate-polyethylene glycol organic chain segment are subjected to a reaction, and the nano material is obtained. According to the invention, the metformin, the polyphenol, the polyethylene glycol and the bisphosphonate are subjected to a specific reaction to prepare the metformin-loaded nano material, so that the whole-body delivery of the metformin can be realized, the curative effect and bioavailability of the metformin on osteoporosis are improved, and meanwhile, the bone targeting property of the metformin is improved.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and / or reversing, returning blood glucose concentration to a normal level in a diabetic.

The invention discloses a method for treating metformin-containing wastewater by using anaerobes, and belongs to the field of sewage treatment. According to the method, an anaerobic membrane reaction device is used for domesticating anaerobic sludge, and a functional flora capable of degrading metformin is obtained. A water outlet and an exhaust port are formed in the top of the device main body, and a water inlet and a sludge discharge port are formed below the side wall of the device main body; the inner cavity is provided with a stirring device, and the outer cavity is a water bath layer. Sewage containing metformin is introduced into a device for inoculating anaerobic sludge, and the input of an external carbon source is gradually reduced, so that microorganisms are directionally enriched by taking metformin as a unique carbon source, and the variety and abundance of the microorganisms are remarkably improved. After domestication, the device continuously treats wastewater, under the condition that the inflow concentration is 21 mg / L of metformin, the degradation rate reaches 80%, the treatment capacity and effect are greatly enhanced, stable treatment of high-concentration metformin can be achieved without additional carbon sources in the later period, and the cost is reduced.

The invention belongs to the technical field of biological medicines, and provides application of combination of nicotinic acid and metformin in blocking the progress of esophageal squamous carcinoma. The invention discovers that nicotinic acid and metformin inhibit FRMD8 expression through different mechanisms for the first time so as to inhibit a JAK1-STAT3 signal channel. Nicotinic acid and metformin are combined to achieve a more remarkable inhibition effect on the ability of esophageal squamous cell carcinoma cells to subcutaneously grow in mice and generate pulmonary metastasis through caudal veins than a single drug, and a brand new drug direction is provided for prevention and treatment of esophageal squamous cell carcinoma.

The application provides a method for simultaneously determining the content of dapagliflozin and metformin, which adopts a reverse-phase high performance liquid chromatography method to separate and determine the content of dapagliflozin and metformin in dapagliflozin and metformin sustained-release tablets. The method has good separation degree, solvent does not interfere with detection, and good method specificity. The detection method is simple, rapid, accurate, high in sensitivity, good in repeatability and accuracy, can quickly and accurately perform qualitative and quantitative analysis on the content of dapagliflozin and metformin hydrochloride in dapagliflozin and metformin sustained-release tablets, and ensures the controllability of the quality of the product.

The application discloses application of metformin in prolonging egg laying time of pigeons, and the metformin prolongs the egg laying time of the pigeons through a glycolysis pathway, and the mass ratio of a dosage of the metformin to a body weight of the pigeons is 60-65 mg:1 kg. It is found through experiments that the metformin can improve oxidative stress, effectively improve total antioxidant capacity in pigeon serum, reduce contents of H2O2 and MDA in the serum, rapidly improve production performance of the pigeons, has effects of promoting nutrient absorption of the body, rapidly recovering damaged functions of the body, and synergistically exerting antioxidation, and simultaneously has advantages of easy absorption of the body, improvement of bioavailability of the medicine and the like.

Methods and compositions are described for treating pancreatic disease, including chronic pancreatitis and / or type 3c diabetes. A pharmaceutical composition of proglumide and metformin is administered to a human subject at a dose of between 250 mg and 2,400 mg proglumide per day, and between 500 mg and 2,500 mg metformin per day.